5VA.F VAXCYTE INC. DL -001
- Market cap
- EUR 9.02B
- P/E
- -
- P/B
- 4.07x
- ROE
- -48.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 5VA.F undervalued?
Graham numberThe Graham number of VAXCYTE INC. DL -001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
VAXCYTE INC. DL -001 fundamental analysis
No fundamental analysis for VAXCYTE INC. DL -001 yet.
VAXCYTE INC. DL -001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About VAXCYTE INC. DL -001
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; …
Full company profileVAXCYTE INC. DL -001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
VAXCYTE INC. DL -001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -102M | -209M | -393M | -570M | -924M | -1.28B |
| EBITDA | - | -214M | -383M | -554M | -899M | -1.24B |
| Net Income | -100M | -223M | -402M | -464M | -767M | -1.20B |
| EPS | -1.89 | -2.81 | -4.22 | -3.71 | -5.85 | -8.06 |
| Balance Sheet | ||||||
| Total Assets | 324M | 1.01B | 1.41B | 3.51B | 3.00B | 2.99B |
| Total Liabilities | 40.3M | 52.6M | 167M | 205M | 317M | 500M |
| Shareholders' Equity | 284M | 954M | 1.24B | 3.31B | 2.69B | 2.49B |
| Cash & Short-term Investments | 69.0M | 835M | 397M | 388M | 174M | 125M |
| Cash Flow | ||||||
| Operating Cash Flow | -121M | -171M | -297M | -453M | -656M | -983M |
| Capital Expenditure | 6.56M | 5.84M | 67.9M | 119M | 57.0M | 32.4M |
| Free Cash Flow | -128M | -176M | -365M | -572M | -713M | -1.02B |
| Ratios | ||||||
| ROE | -35.2% | -23.4% | -32.4% | -14.0% | -28.5% | -48.3% |
| ROA | -30.9% | -22.2% | -28.6% | -13.2% | -25.5% | -40.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
VAXCYTE INC. DL -001 dividends
VAXCYTE INC. DL -001 has not paid dividends in the last 5 fiscal years.
Who owns VAXCYTE INC. DL -001
- Insiders 0.47%
- Institutions 99.53%
- Public & others 0.00%
- Shares outstanding 158M
- Free float 146M
VAXCYTE INC. DL -001 company profile
- Company name
- VAXCYTE INC. DL -001
- Ticker
- 5VA.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 507
- Fiscal year end
- December
- Address
- 825 Industrial Road, San Carlos, CA, United States, 94070
- Phone
- 650 837 0111
- Website
- vaxcyte.com
About VAXCYTE INC. DL -001
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
VAXCYTE INC. DL -001 management
10- Mr. Grant E. Pickering M.B.A.Co-Founder, CEO & Director · born 1968
- Mr. Andrew L. Guggenhime M.B.A.President & CFO · born 1968
- Mr. James T. Wassil M.B.A., M.S.Executive VP, Chief Scientific Officer & COO · born 1969
- Mr. Harpreet S. Dhaliwal M.B.A.Chief Technical Operations Officer · born 1973
- Dr. Jeff Fairman Ph.D.Co-Founder & VP of Research · born 1964
- Ms. Elvia CowanSenior VP of Finance & Chief Accounting Officer · born 1973
- Mr. Jeff MacdonaldExecutive Director of Investor Relations
- Mr. David McAvoy J.D.Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
- Ms. Whitney JonesChief People Officer
- Ms. Janet GraesserSenior Vice President of Corporate Affairs